Bruce E. Sands, MD, MS, chief of the Dr. Henry D. Janowitz division of gastroenterology at the Icahn School of Medicine at Mount Sinai, discusses results of a recent study on the combination of gesulkemab and golimumab, which demonstrated higher rates of clinical response, endoscopic improvements, and remission in patients with moderate-to-severe ulcerative colitis. According to Dr Sands, this is the first study of combined biologic agents in a blinded, randomized, controlled fashion to demonstrate additive, if not synergistic, efficacy of anti-TNF and anti-IL-23 antibody therapy. Notably, there did not seem to be additive risk of safety events.

View video by clicking here.